Trial Profile
A retrospective study assesssing Imatinib and Dasatinibib as salvage therapy in severe sclerotic chronic graft-vs-host disease (scGVHD).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2017
Price :
$35
*
At a glance
- Drugs Dasantafil (Primary) ; Imatinib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2017 New trial record